Global Interventional Oncology Market Growth, Size, Trends Analysis- By Technique, By Procedure, By Applications, By End-use- Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Interventional Oncology Market Introduction and Overview

According to SPER market research, 'Global Interventional Oncology Market Size- By Technique, By Procedure, By Applications, By End-use- Regional Outlook, Competitive Strategies and Segment Forecast to 2034' states that Global Interventional Oncology Market is projected to be worth 6.29 billion by 2034 and is anticipated to surge at a CAGR of 8.83%.

A speciality area of medicine called interventional oncology focuses on using minimally invasive, image-guided techniques to diagnose and treat cancer. It encompasses techniques such as tumor ablation, embolization, and targeted drug delivery, which allow physicians to treat cancerous tissues accurately while minimizing harm to surrounding healthy areas. These approaches offer significant advantages over conventional treatments like surgery and radiation, including shorter recovery times, fewer complications, and enhanced patient comfort.

Restraints: The Global Interventional Oncology Market is facing several challenges due to the high cost of procedures, which limits widespread adoption. Treatments such as TACE, TARE, and percutaneous ablation require advanced and specialized equipment, including Yttrium-90, sophisticated catheters, embolic agents, and state-of-the-art imaging systems, making production and scaling expensive. Additionally, these procedures demand highly skilled interventional radiologists and trained support staff, further increasing overall costs.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Technique, By Procedure, By Applications, By End-use

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

AngioDynamics Inc., Boston Scientific Corporation, Cook Medical, GE Healthcare, Johnson & Johnson (Ethicon), Medtronic plc, Profound Medical, Siemens Healthineers, Stryker Corporation, and Teleflex Incorporated.

Global Interventional Oncology Market Segmentation:

By Technique: Based on the Technique, Global Interventional Oncology Market is segmented as; Ablation Therapies, Embolization Therapies.

By Procedure: Based on the Procedure, Global Interventional Oncology Market is segmented as; Tumor Ablation, Tumor Biopsy, Vascular Intervention, Palliative Care.

By Applications: Based on the Applications, Global Interventional Oncology Market is segmented as; Liver Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Breast Cancer.

By End-Use: Based on the End-Use, Global Interventional Oncology Market is segmented as; Hospitals, Specialty Clinics.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: MEDE2571

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Interventional Oncology Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Interventional Oncology Market

7.Global Interventional Oncology Market, By Technique (USD Million) 2021-2034

7.1.Ablation Therapies
- 7.1.1.Radiofrequency Ablation (RFA)
- 7.1.2.Microwave Ablation (MWA)
- 7.1.3.Cryoablation
- 7.1.4.Laser Ablation
- 7.1.5.Irreversible Electroporation (IRE)
7.2.Embolization Therapies
- 7.2.1.Transarterial Chemoembolization (TACE)
- 7.2.2.Transarterial Radioembolization (TARE)
7.3.Biopsy Techniques
- 7.3.1.Core Needle Biopsy
- 7.3.2.Fine Needle Aspiration (FNA)
7.4.Targeted Therapy Delivery Systems
- 7.4.1.Drug-Eluting Beads
- 7.4.2.Radioembolization
- 7.4.3.Drug-Eluting Stents
- 7.4.4.Injectable Hydrogels and Nanoparticles
- 7.4.5.Other Targeted Therapy Systems
7.5.Image-Guided Procedures
- 7.5.1.Ultrasound Guidance
- 7.5.2.CT Scan Guidance
- 7.5.3.MRI Guidance
- 7.5.4.Fluoroscopy Guidance

8.Global Interventional Oncology Market, By Procedure (USD Million) 2021-2034

8.1.Tumor Ablation
8.2.Tumor Biopsy
8.3.Vascular Interventions
8.4.Palliative Care

9.Global Interventional Oncology Market, By Applications (USD Million) 2021-2034

9.1.Liver Cancer
9.2.Lung Cancer
9.3.Kidney Cancer
9.4.Prostate Cancer
9.5.Breast Cancer
9.6.Other Cancer

10.Global Interventional Oncology Market, By End-Use (USD Million) 2021-2034

10.1.Hospitals
10.2.Specialty Clinics

11.Global Interventional Oncology Market, (USD Million) 2021-2034

11.1.Global Interventional Oncology Market Size and Market Share

12.Global Interventional Oncology Market, By Region, (USD Million) 2021-2034

12.1.Asia-Pacific
- 12.1.1.Australia
- 12.1.2.China
- 12.1.3.India
- 12.1.4.Japan
- 12.1.5.South Korea
- 12.1.6.Rest of Asia-Pacific
12.2.Europe
- 12.2.1.France
- 12.2.2.Germany
- 12.2.3.Italy
- 12.2.4.Spain
- 12.2.5.United Kingdom
- 12.2.6.Rest of Europe
12.3.Middle East and Africa
- 12.3.1.Kingdom of Saudi Arabia
- 12.3.2.United Arab Emirates
- 12.3.3.Qatar
- 12.3.4.South Africa
- 12.3.5.Egypt
- 12.3.6.Morocco
- 12.3.7.Nigeria
- 12.3.8.Rest of Middle-East and Africa
12.4.North America
- 12.4.1.Canada
- 12.4.2.Mexico
- 12.4.3.United States
12.5.Latin America
- 12.5.1.Argentina
- 12.5.2.Brazil
- 12.5.3.Rest of Latin America

13.Company Profile

13.1.AngioDynamics Inc.
- 13.1.1.Company details
- 13.1.2.Financial outlook
- 13.1.3.Product summary
- 13.1.4.Recent developments
13.2.Boston Scientific Corporation
- 13.2.1.Company details
- 13.2.2.Financial outlook
- 13.2.3.Product summary
- 13.2.4.Recent developments
13.3.Cook Medical
- 13.3.1.Company details
- 13.3.2.Financial outlook
- 13.3.3.Product summary
- 13.3.4.Recent developments
13.4.GE Healthcare
- 13.4.1.Company details
- 13.4.2.Financial outlook
- 13.4.3.Product summary
- 13.4.4.Recent developments
13.5.Johnson & Johnson (Ethicon)
- 13.5.1.Company details
- 13.5.2.Financial outlook
- 13.5.3.Product summary
- 13.5.4.Recent developments
13.6.Medtronic plc
- 13.6.1.Company details
- 13.6.2.Financial outlook
- 13.6.3.Product summary
- 13.6.4.Recent developments
13.7.Profound Medical
- 13.7.1.Company details
- 13.7.2.Financial outlook
- 13.7.3.Product summary
- 13.7.4.Recent developments
13.8.Siemens Healthineers
- 13.8.1.Company details
- 13.8.2.Financial outlook
- 13.8.3.Product summary
- 13.8.4.Recent developments
13.9.Stryker Corporation
- 13.9.1.Company details
- 13.9.2.Financial outlook
- 13.9.3.Product summary
13.10.Teleflex Incorporated
- 13.10.1.Company details
- 13.10.2.Financial outlook
- 13.10.3.Product summary
- 13.10.4.Recent developments
13.11.Others